Is bigger better? Analysis of efficacy and safety of lemborexant 5 versus 10 mg in insomnia patients

Lemborexant 10 mg is generally not advisable as an initial or escalated dose due to higher harm risk and unlikely clinical benefit.

Authors

Institutions

Publication Details

Journal
International Journal of Pharmacy Practice
Published
2025-09-27
DOI
https://doi.org/10.1093/ijpp/riaf077
Primary Topic
Sleep and related disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Is bigger better? Analysis of efficacy and safety of lemborexant 5 versus 10 mg in insomnia patients

Aaron M Tejani, Eugene Chang
International Journal of Pharmacy Practice
Sleep and related disorders
article

Is bigger better? Analysis of efficacy and safety of lemborexant 5 versus 10 mg in insomnia patients

Aaron M Tejani, Eugene Chang
article en

Abstract

Lemborexant 10 mg is generally not advisable as an initial or escalated dose due to higher harm risk and unlikely clinical benefit.

International Journal of Pharmacy Practice
University of British Columbia (CA), Fraser Health (CA), Vancouver General Hospital (CA)
Openalex Percentile: Top 73%
Sleep and related disorders
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Is bigger better? Analysis of efficacy and safety of lemborexant 5 versus 10 mg in insomnia patients — Aaron M Tejani, Eugene Chang · International Journal of Pharmacy Practice (2025) | TGRS Research Map | TGRS